期刊文献+
共找到1,696篇文章
< 1 2 85 >
每页显示 20 50 100
Changes of Expressions of VEGF, bFGF, and Angiogenesis, and Effect of Benazepril, bFGF on Angiogenesis in Acute Myocardial Infarction Model of the Rabbits 被引量:12
1
作者 DAN-YANGLI KUIZHAO +2 位作者 JUN-FUZHOU PENGCHEN WEILI 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2004年第4期442-451,共10页
Objective To explore the changes of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and angiogenesis, and the effects of bFGF, angiotensin converting enzyme inhibiter(ACEI) benazepril... Objective To explore the changes of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and angiogenesis, and the effects of bFGF, angiotensin converting enzyme inhibiter(ACEI) benazepril on the angiogenesis in acute myocardial infarction (AMI) model of rabbits, and to provide a probable evidence for the treatment of AMI. Methods AMI model was established by ligating anterior descending branch of coronary artery of Japan-Sino hybridization white rabbits. The postoperative rabbits were randomly divided into 6 groups and each group was treated with different drugs. Groups 1 and 2 were treated with normal saline (NS) for 28 and 14 days (d), group 3 and 4 with bFGF for 28 and 14 d, groups 5 with benazepril for 14 d, and group 6 with benazepril and bFGF for 14 d respectively. The rabbits were killed on the 14th or 28th d and their hearts were excised, sectioned and stained with HE, Masson trichrome to observe VEGF, bFGF and CD34 under a microscope, which were quantified with a computer-assisted morphometry. Results Compared with group 1, the granulation tissue of infarction zone (IZ) in group 2 freshened up, and the capillary density (CD) in IZ was increased (P=0.002). The CD in the IZ as well as VEGF and bFGF in groups 3 and 4 were increased respectively (P=0.011-0.037). In group 5 the changes of VEGF and bFGF were not found in the IZ and the border zone (BZ) while CD was significantly increased (35.4% and 25.6%, P=0.036 and 0.037). Compared with group 2, the CD in the IZ and BZ of group 6 was significantly increased (63.4% and 44.3% P=0.007 and 0.007), meanwhile VEGF and bFGF were increased. Compared with group 5, only VEGF was increased. Conclusion Intravenous bFGF may increase VEGF and bFGF significantly, thus promoting the angiogenesis in the IZ and BZ in cardiac infarction as VEGF and bFGF are the potent angiogenic growth factors. Benazepril may promote angiogenesis in the IZ and BZ in cardiac infarction, but its mechanism is irrelative to the expression of VEGF and bFGF. The combination of benazepril and bFGF may promote, to some extent, the expression of VEGF and bFGF, but their effect on angiogenesis has not been found. 展开更多
关键词 Myocardial infarction ANGIOGENESIS Basic fibroblast growth factor Vascular endothelial growth factor benazepril
下载PDF
Benazepril和Losartan对培养SHR心肌成纤维细胞增殖及合成胶原影响 被引量:2
2
作者 谢良地 陈水龙 +2 位作者 许昌声 王华军 吴可贵 《高血压杂志》 CAS CSCD 2001年第1期62-64,共3页
目的 观察血管紧张素Ⅱ (AngⅡ )、苯那普利 (Benazepril,Be na)、洛沙坦 (Losartan)对培养的SHR和WKY大鼠心肌成纤维细胞 (CFb)增殖及合成胶原的影响。方法 采用组织块贴壁法培养CFb ,分别测定AngⅡ、Bena干预下CFb的增殖情况 ,AngⅡ... 目的 观察血管紧张素Ⅱ (AngⅡ )、苯那普利 (Benazepril,Be na)、洛沙坦 (Losartan)对培养的SHR和WKY大鼠心肌成纤维细胞 (CFb)增殖及合成胶原的影响。方法 采用组织块贴壁法培养CFb ,分别测定AngⅡ、Bena干预下CFb的增殖情况 ,AngⅡ、Bena和Losartan干预下CFb的3H 脯氨酸 (3H Proline)掺入量。结果 各种浓度的AngⅡ (10 -10 mol~ 10 -6mol)和Bena(10 -9mol~ 10 -5mol)对CFb的细胞数显著增殖无影响 ,AngⅡ呈浓度依赖性促进CFb的3H Proline掺入量 ,Bena抑制CFb的3H Proline掺入量 ,Losartan呈浓度依赖性抑制 10 -7molAngⅡ诱导的CFb的胶原合成。结论 AngⅡ和Bena不影响CFb的增殖 ,AngⅡ对CFb的胶原合成有促进作用 ,Bena抑制CFb胶原合成 。 展开更多
关键词 心肌成纤维细胞 高血压 血管紧张素Ⅱ 苯那普利 洛沙坦
下载PDF
Effects of the Combined Use of Benazepril and Valsartan on Apoptosis in the Kidney of Rats with Adriamycin-induced Nephritic Glomerulosclerosis 被引量:1
3
作者 韩子明 邢燕 +2 位作者 王宏伟 梁秀玲 周建华 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2004年第3期254-258,共5页
Summary: The effects of the combined use of angiotensin converting enzyme inhibitor (ACEI) benazepril and angiotensin Ⅱ type 1 receptor antagonist (AT1RA) valsartan on apoptosis and the expression of apoptosis-relat... Summary: The effects of the combined use of angiotensin converting enzyme inhibitor (ACEI) benazepril and angiotensin Ⅱ type 1 receptor antagonist (AT1RA) valsartan on apoptosis and the expression of apoptosis-related proteins Fas and FasL in the kidney of rats with adriamycin-induced nephritic glomerulosclerosis was investigated. Uninephrectomy and the injection of adriamycin induced the rat model of glomerulosclerosis. Benazepril (6 mg/kg), valsantan (20 mg/kg), or benazepril (3 mg/kg) plus valsantan (20 mg/kg) was respectively delivered daily by gavage to the rats in three treatment groups for 12 weeks. Apoptosis was examined by means of terminal-deoxynucleotidyl transferase mediated d-UTP nick end labeling (TUNEL). Immunohistochemistry was adopted to detect the expression of Fas and FasL. Software of pathological analysis quantitated the levels of Fas and FasL. The results showed that as compared with those in the control group, the kidneys in the model group had more severe glomerulosclerosis, much more apoptotic cells and higher levels of expression of Fas and FasL. The degree of glomerulosclerosis, the number of apoptotic cells and the levels of expression of Fas and FasL were reduced by benazepril and valsartan. The combined use of benazepril and valsartan had the best therapeutic effect. It was concluded that benazepril and valsartan could suppress the excessive apoptosis of kidney cells by lowering the expression of the apoptosis-related proteins Fas and FasL, so as to postpone the process of glomerulosclerosis. The combined use of benazepril and valsartan has better therapeutic effect. 展开更多
关键词 benazepril VALSARTAN adriamycin nephropathy APOPTOSIS Fas FASL
下载PDF
Effects of Chronotherapy of Benazepril on the Diurnal Profile of RAAS and Clock Genes in the Kidney of 5/6 Nephrectomy Rats 被引量:1
4
作者 黄小妹 袁静萍 +3 位作者 曾星若 彭彩霞 梅啓慧 陈文莉 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2013年第3期368-374,共7页
Summary: This study investigated the effects of benazepril administered in the morning or evening on the diurnal variation of renin-angiotensin-aldosterone system (RAAS) and clock genes in the kidney. The male Wist... Summary: This study investigated the effects of benazepril administered in the morning or evening on the diurnal variation of renin-angiotensin-aldosterone system (RAAS) and clock genes in the kidney. The male Wistar rat models of 5/6 subtotal nephrectomy (STNx) were established. Animals were ran- domly divided into 4 groups: sham STNx group (control), STNx group, morning benazepril group (MB) and evening benazepril group (EB). Benazepril was intragastfically administered at a dose of 10 mg/kg/day at 07:00 and 19:00 in the MB group and EB group respectively for 12 weeks. All the animals were synchronized to the light:dark cycle of 12:12 for 12 weeks. Systolic blood pressure (SBP), 24-h urinary protein excretion and renal function were measured at 11 weeks. Blood samples and kidneys were collected every 4 h throughout a day to detect the expression pattern of renin activity (RA), angio- tensin Ⅱ (Ang Ⅱ ) and aldosterone (Aid) by radioimmunoassay (RIA) and the mRNA expression profile of clock genes (bmall, dbp and per2) by real-time PCR at 12 weeks. Our results showed that no signifi- cant differences were noted in the SBP, 24-h urine protein excretion and renal function between the MB and EB groups. There were no significant differences in average Aid and RA content of a day between the MB group and EB group. The expression peak of bmall mRNA was phase-delayed by 4 to 8 h, and the diurnal variation of per2 and dbp mRNA diminished in the MB and EB groups compared with the control and STNx groups. It was concluded when the similar SBP reduction, RAAS inhibition and clock gene profile were achieved with optimal dose of benazepril, morning versus evening dosing of benazepril has the same renoprotection effects. 展开更多
关键词 CHRONOTHERAPY benazepril RAAS CIRCADIAN clock genes 5/6 subtotal nephrectomy
下载PDF
New Stability Indicating Method for Quantification of Impurities in Amlodipine and Benazepril Capsules by Validated HPLC 被引量:1
5
作者 Rama Joga Venkata Eranki Gopichand Inti +3 位作者 Venkatasubramanian Jayaraman Raghuram Pannala Sudhakar Rao Vidiyala Jadi Sree Ramulu 《American Journal of Analytical Chemistry》 2013年第12期715-724,共10页
A stability indicating LC method was developed for the simultaneous determination of Amlodipine and Benazepril capsules in pharmaceutical dosage form. Efficient chromatographic separation was achieved on Symmetry C18 ... A stability indicating LC method was developed for the simultaneous determination of Amlodipine and Benazepril capsules in pharmaceutical dosage form. Efficient chromatographic separation was achieved on Symmetry C18 stationary phase with simple combination of amobile phase containing 750 mL of DI Water, 250 mL of Acetonitrile and 2 mL of Octylamine into suitable container with adjusted pH to 2.50 ± 0.05 with the aid of Ortho phosphoric acid delivered in an isocratic mode and quantification was carried out using UV detection at 240 nm at a flow rate of 1.0 mL·min-1 with an injection volume of 20 μl and ambient column temperature. This method is capable to detect both the drug components of Amlodipine and Benazepril in presence of their degradation products (Amlodipine Imp-A and Benazepril Impurity-C) with a detection level of 0.05%. Amlodipine/Benazepril in their combination drug product were exposed to thermal, photolytic, hydrolytic and oxidative stress conditions, and the samples were analysed. Peak homogeneity data of Amlodipine and Benazeprilis were obtained using PDA detector, in the stressed sample chromatograms, demonstrating the specificity. The method shows excellent linearity over a range of 0.05%-2.0% for Amlodipine, Amlodipine Impurity-A and 0.05%-5.0% for Benazepril and Benazepril Impurity-C. The correlation coefficient for Amlodipine and Benazepril is 1. The relative standard deviation was always less than 2%. The proposed method was found to be suitable and accurate for quantitative determination and the stability study of Amlodipine and Benazepril in pharmaceutical preparations. The developed HPLC method was validated with respect to linearity & range, accuracy, precision and robustness. 展开更多
关键词 COLUMN Liquid CHROMATOGRAPHY Method Validation Stability Indicating Study AMLODIPINE and benazepril
下载PDF
Protective effect of calcium dobesilate combined with benazepril therapy on renal injury in patients with early diabetic nephropathy and the possible molecular mechanisms
6
作者 Ling Zhang Yi-Ming Li +4 位作者 Zhi-Fang Wang Xiao-Zhen Xing Liang Zhu Jin-Xiao Jiang Qing-Hong Lyu 《Journal of Hainan Medical University》 2017年第6期48-52,共5页
Objective:To explore the protective effect of calcium dobesilate combined with benazepril therapy on renal injury in patients with early diabetic nephropathy and the possible molecular mechanisms.Methods:A total of 50... Objective:To explore the protective effect of calcium dobesilate combined with benazepril therapy on renal injury in patients with early diabetic nephropathy and the possible molecular mechanisms.Methods:A total of 50 patients with early diabetic nephropathy treated in our hospital between May 2012 and January 2016 were collected, and according to the random number table, the patients were divided into observation group (n=25) and control group (n=25). On the basis of conventional treatment, control group of patients received benazepril therapy, observation group of patients received calcium dobesilate combined with benazepril therapy, and the treatment lasted for 3 months. Before and after treatment, automatic biochemical analyzer was used to detect the levels of renal injury indexes in peripheral blood, RIA method was used to detect the levels of renal injury indexes in urine, ELISA method was used to detect the levels of renal fibrosis indexes and Western-blot method was used to detect the protein expression of TGF-β1/BMP-7 and Smad signaling pathway molecules in renal tissue. Results: Before treatment, differences in renal injury index levels, renal fibrosis index levels and signaling pathway molecule protein expression were not statistically significant between two groups of patients. After treatment, BUN, SCr andβ-TP levels in the peripheral blood as well as KIM-1 level in urine of observation group were lower than those of control group;renal fibrosis indexes TGF-β1, CTGF, TIMP-1, LN and HA levels in serum of observation group were lower than those of control group;TGF-β1 and Smad2/3 protein expression in renal tissue of observation group were lower than those of control group while Smad7 and BMP-7 protein expression were higher than those of control group.Conclusion: Calcium dobesilate combined with benazepril therapy can reduce the renal injury and inhibit the fibrosis process in patients with early diabetic nephropathy, and it achieves the above effect by regulating the TGF-β1/BMP-7 and Smad signaling pathway function. 展开更多
关键词 Early DIABETIC NEPHROPATHY Calcium dobesilate benazepril RENAL injury
下载PDF
New process for preparing benazepril precursor
7
作者 Kafssi Hassan 王涛 +1 位作者 王芳 万平玉 《化工学报》 EI CAS CSCD 北大核心 2007年第10期2558-2560,共3页
The present work relates to a new synthesis process for the preparation of 3-[(1-ethoxycarbonyl-3-phenylpropyl)-amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetate tert butyl ester(EPTAB),the precursor of benaz... The present work relates to a new synthesis process for the preparation of 3-[(1-ethoxycarbonyl-3-phenylpropyl)-amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetate tert butyl ester(EPTAB),the precursor of benazepril HCl.The reaction conditions were optimized.The diastereomeric products were separated by flash column chromatography.The structures of the products were characterized with IR and NMR. 展开更多
关键词 制备 前体 血管紧缩素转换酶 盐酸贝那普利
下载PDF
益气养阴通络汤联合贝那普利治疗糖尿病肾病疗效及对血清TGF-β1、VEGF指标影响 被引量:1
8
作者 陈仕银 胡朋 《中华中医药学刊》 CAS 北大核心 2024年第3期238-242,共5页
目的探讨益气养阴通络汤联合贝那普利治疗糖尿病肾病(diabetic nephropathy,DN)的疗效及对转化生长因子-β_(1)(transforming growth factor-β_(1),TGF-β_(1)),血管内皮生长因子(vascular endothelial growth factor,VEGF)影响。方法... 目的探讨益气养阴通络汤联合贝那普利治疗糖尿病肾病(diabetic nephropathy,DN)的疗效及对转化生长因子-β_(1)(transforming growth factor-β_(1),TGF-β_(1)),血管内皮生长因子(vascular endothelial growth factor,VEGF)影响。方法选取2019年10月—2021年10月医院收治的DN病人94例,随机分为对照组(n=48)和观察组(n=46)。入院后两组病人均实施生活方式相关的指导,包括体质量控制、运动、戒烟酒等,给予脂质的代谢紊乱相关纠正、血糖控制、血压等基础的治疗,对照组实施盐酸贝那普利片的口服治疗,观察组则在此基础上实施益气养阴通络汤治疗,两组持续治疗4周。对比两组临床疗效、尿微量白蛋白(microalbumin,mALB)、尿白蛋白肌酐比(urine albumin creatine ratio,UACR)、β_(2)微球蛋白(β_(2)-microglobulin,β_(2)-MG)水平、中医证候评分、血清同型半胱氨酸(homocysteine,Hcy)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(Interleukin-6,IL-6)、血清TGF-β_(1)和VEGF及空腹血糖(fasting plasma glucose/fasting blood glucose,FPG)、餐后2 h血糖(2 hour postprandial blood glucose,2 h PG)和糖化血红蛋白(glyeosylated hemoglobin,HbAlc)指标变化。结果治疗前两组mALB、UACR、β_(2)-MG指标间无统计学意义(P>0.05);治疗后两组mALB、UACR、β_(2)-MG指标较治疗前显著降低(P<0.05);并且观察组降低较明显(P<0.05);观察组治疗总有效率较对照组明显较高(P<0.05);治疗后两组主症评分、次症评分和中医证候总评分明显降低(P<0.05);且观察组降低较明显(P<0.05);治疗后两组血清Hcy、TNF-α、IL-6指标明显降低(P<0.05);且观察组降低较明显(P<0.05);治疗后两组血清TGF-β_(1)和VEGF指标较治疗前明显降低(P<0.05);且观察组降低较明显(P<0.05);治疗后两组FPG、2 h PG和HbAlc指标较治疗前明显降低(P<0.05);且观察组降低较明显(P<0.05)。结论采用益气养阴通络汤联合贝那普利治疗DN具有较好的临床疗效,可降低血清TGF-β_(1),VEGF指标,降低蛋白尿水平。 展开更多
关键词 益气养阴通络汤 贝那普利 糖尿病肾病 临床疗效 血清TGF-Β1 VEGF
下载PDF
盐酸贝那普利片及活性代谢物在中国健康受试者中的生物等效性研究
9
作者 段舟萍 彭洪薇 +3 位作者 李蒲 魏筱华 崔建鑫 韩盈 《南昌大学学报(医学版)》 2024年第1期50-53,59,共5页
目的评价空腹及餐后状态下单次口服盐酸贝那普利片受试和参比制剂的生物等效性。方法将志愿者按照1:1的比例分配至T-R(受试制剂-参比制剂)和R-T(参比制剂-受试制剂)序列组;采用单中心、随机、开放、两周期、双序列、自身交叉、单次给药... 目的评价空腹及餐后状态下单次口服盐酸贝那普利片受试和参比制剂的生物等效性。方法将志愿者按照1:1的比例分配至T-R(受试制剂-参比制剂)和R-T(参比制剂-受试制剂)序列组;采用单中心、随机、开放、两周期、双序列、自身交叉、单次给药(空腹、餐后)的试验方法设计;采用高效液相-色谱串联质谱法测定血药浓度;使用WinNonlin软件的非房室模型对贝那普利主要药代动力学参数C max、AUC 0-t、AUC 0-∞进行分析;T max采用非参数秩和检验。结果空腹组受试制剂和参比制剂贝那普利的主要药代动力学参数如下:C max分别为(207.86±70.77)ng·mL^(-1)和(205.20±70.37)ng·mL^(-1);AUC 0-t分别为(168.91±36.03)h×ng·mL^(-1)和(170.23±38.37)h×ng·mL^(-1);AUC 0-∞分别为(171.01±36.15)h×ng·mL^(-1)和(172.27±38.49)h×ng·mL^(-1);T max分别为(0.48±0.11)h和(0.49±0.17)h。空腹组受试制剂和参比制剂活性代谢物贝那普利拉的主要药代动力学参数如下:C max分别为(270.45±69.07)ng·mL^(-1)和(271.86±65.90)ng·mL^(-1);AUC 0-t分别为(1490.10±295.32)h×ng·mL^(-1)和(1487.96±285.39)h×ng·mL^(-1);AUC 0-∞分别为(1535.19±289.52)h×ng·mL^(-1)和(1532.63±285.26)h×ng·mL^(-1);T max分别为(1.45±0.47)h和(1.41±0.33)h。餐后组受试制剂和参比制剂贝那普利的C max分别为(102.05±41.17)ng·mL^(-1)和(112.04±49.39)ng·mL^(-1);AUC 0-t分别为(149.19±32.76)h×ng·mL^(-1)和(151.70±33.78)h×ng·mL^(-1);AUC 0-∞分别为(151.02±33.08)h×ng·mL^(-1)和(154.03±33.99)h×ng·mL^(-1);T max分别为(1.14±0.65)h和(1.09±0.60)h。餐后组受试制剂和参比制剂的活性代谢物贝那普利拉的C max分别为(207.71±50.76)ng·mL^(-1)和(211.68±66.50)ng·mL^(-1);AUC 0-t分别为(1366.01±292.24)h×ng·mL^(-1)和(1343.78±315.41)h×ng·mL^(-1);AUC 0-∞分别为(1414.95±297.71)h×ng·mL^(-1)和(1387.03±314.17)h×ng·mL^(-1);T max分别为(2.46±0.87)h和(2.46±0.85)h。受试制剂与参比制剂贝那普利和贝那普利拉的C max、AUC 0-t、AUC 0-∞的几何均值比值的90%置信区间均在80%~125%;T max在两种制剂间差异无统计学意义(P>0.05)。结论盐酸贝那普利片的受试制剂和参比制剂具有生物等效性。 展开更多
关键词 贝那普利 贝那普利拉 生物等效性 药代动力学 血管紧张素转化酶抑制剂
下载PDF
胰激肽原酶辅助治疗糖尿病肾病的临床疗效及对患者肾功能与血糖水平和炎症因子的影响
10
作者 马晶 梁桂敏 《当代医学》 2024年第1期82-85,共4页
目的探讨胰激肽原酶辅助治疗糖尿病肾病(DN)患者的临床疗效。方法选取2020年2月至2021年10月哈尔滨市第一医院收治的113例DN患者作为研究对象,按照随机数字表法分为B组(n=56)与A组(n=57)。B组给予贝那普利治疗,A组在B组基础上联合胰激... 目的探讨胰激肽原酶辅助治疗糖尿病肾病(DN)患者的临床疗效。方法选取2020年2月至2021年10月哈尔滨市第一医院收治的113例DN患者作为研究对象,按照随机数字表法分为B组(n=56)与A组(n=57)。B组给予贝那普利治疗,A组在B组基础上联合胰激肽原酶辅助治疗,比较两组临床疗效、肾功能、血糖水平、炎症因子和25-羟维生素D_(3)[25-(OH)D_(3)]水平及不良反应发生率。结果A组治疗总有效率高于B组(93.18%vs.76.75%),差异有统计学意义(P<0.05)。治疗12周后,两组24h尿蛋白水平、尿微量白蛋白/尿肌酐比值(UACR)、24h微量白蛋白排泄率(UAER)均低于治疗前,且A组低于B组,差异有统计学意义(P<0.05)。治疗12周后,两组糖化血红蛋白A1c(HbA1c)、空腹血糖(FBG)和餐后2h血糖(2hPBG)水平均低于治疗前,且A组低于B组,差异有统计学意义(P<0.05)。治疗12周后,两组肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)水平均低于治疗前,25-(OH)D_(3)、白细胞介素2(IL-2)水平均高于治疗前,且A组TNF-α、IL-6水平均低于B组,25-(OH)D_(3)、IL-2水平均高于B组,差异有统计学意义(P<0.05)。A组与B组不良反应发生率(12.25%vs.8.95%)比较差异无统计学意义。结论胰激肽原酶辅助治疗DN效果显著,可明显降低炎症因子水平,改善患者肾功能和25-(OH)D_(3)水平,控制血糖稳定,且不增加不良反应的发生。 展开更多
关键词 糖尿病肾病 胰激肽原酶 贝那普利 肾功能 炎症因子 血糖
下载PDF
阿托伐他汀联合贝那普利对高血压患者的降压疗效分析
11
作者 周静 《中国现代药物应用》 2024年第9期89-92,共4页
目的探讨阿托伐他汀联合贝那普利对高血压患者的降压疗效。方法92例高血压患者,根据数字方法分成对照组和观察组,每组46例。对照组给予贝那普利口服治疗,观察组给予阿托伐他汀联合贝那普利口服治疗。比较两组患者治疗前后的动态血压[24 ... 目的探讨阿托伐他汀联合贝那普利对高血压患者的降压疗效。方法92例高血压患者,根据数字方法分成对照组和观察组,每组46例。对照组给予贝那普利口服治疗,观察组给予阿托伐他汀联合贝那普利口服治疗。比较两组患者治疗前后的动态血压[24 h收缩压(SBP)、24 h舒张压(DBP)、24 h脉压(PP)、24 h脉压指数(PPI)]、血脂[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]水平、颈动脉内膜中层厚度(IMT)、超敏C反应蛋白(hs-CRP)水平以及安全性。结果治疗后,观察组患者24 h SBP(143.56±6.20)mm Hg(1 mm Hg=0.133 kPa)、24 h DBP(87.60±4.51)mm Hg、24 h PP(50.79±7.48)mm Hg均低于对照组的(148.12±8.63)、(90.18±5.35)、(56.67±5.32)mm Hg,差异明显(P<0.05);治疗后两组24 h PPI水平无明显差异(P>0.05)。治疗后,观察组患者TC(4.02±0.75)mmol/L、TG(1.74±0.67)mmol/L、LDL-C(2.43±0.57)mmol/L均低于对照组的(5.13±1.10)、(2.04±0.58)、(2.83±0.62)mmol/L,差异明显(P<0.05);两组患者治疗后的HDL-C水平无明显差异(P>0.05)。治疗后,观察组患者IMT(0.73±0.10)mm、hs-CRP(3.27±1.20)mg/L低于对照组的(0.80±0.14)mm、(4.68±1.35)mg/L,差异明显(P<0.05)。治疗期间两组未出现明显药物不良反应。结论阿托伐他汀联合贝那普利治疗高血压能提高降压疗效,患者的血脂水平得以调节,减轻炎症反应,稳定斑块,安全可靠。 展开更多
关键词 高血压 阿托伐他汀 贝那普利 血压 血脂 动脉硬化
下载PDF
乌拉地尔联合贝那普利治疗冠心病合并心力衰竭患者的价值
12
作者 张娜 朱红利 +4 位作者 李雪青 崔艳敏 宫阳阳 刘倩 宋岳涵 《分子诊断与治疗杂志》 2024年第6期1024-1027,共4页
目的 探究乌拉地尔联合贝那普利治疗冠心病合并心力衰竭患者的价值。方法 研究2020年11月至2023年11月收治的118例冠心病合并心力衰竭患者,采用随机数字表法将上述患者分为观察组(n=59,采用乌拉地尔联合贝那普利治疗)和对照组(n=59,单... 目的 探究乌拉地尔联合贝那普利治疗冠心病合并心力衰竭患者的价值。方法 研究2020年11月至2023年11月收治的118例冠心病合并心力衰竭患者,采用随机数字表法将上述患者分为观察组(n=59,采用乌拉地尔联合贝那普利治疗)和对照组(n=59,单独采用贝那普利治疗),治疗一个月后比较两组患者疗效、心功能、NT-proBNP水平差异、运动耐力及不良反应发生情况。结果 观察组总有效率相较于对照组更高,差异有统计学意义(χ^(2)=4.827, P<0.05);相较于治疗前,治疗后两组患者左心室射血分数(LVEF)、每分钟搏出量(SV)均有上升,且观察组相较于对照组均更高,差异有统计学意义(t=2.345、3.198, P<0.05);相较于治疗前,治疗后两组患者左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均有下降,且观察组相较于对照组均更低,差异有统计学意义(t=2.265、2.007, P<0.05);相较于治疗前,治疗后两组患者6分钟步行距离(6MWT)均有上升,且观察组相较于对照组均更高,差异有统计学意义(t=2.018, P<0.05);相较于治疗前,治疗后两组患者NT-proBNP水平均有下降,且观察组相较于对照组均更低,差异有统计学意义(t=3.575, P<0.05);比较两组患者不良反应总发生率无统计意义(P>0.05)。结论 乌拉地尔联合贝那普利治疗在冠心病合并心力衰竭患者中具有较高应用应用价值。 展开更多
关键词 乌拉地尔 贝那普利 冠心病 心力衰竭 氨基末端脑利钠肽前体
下载PDF
氨氯地平贝那普利片在老年高血压合并急性心肌梗死患者中的临床疗效分析
13
作者 刘旭 佟岩 +2 位作者 伏秋 李海涛 王帅 《当代医学》 2024年第6期9-14,共6页
目的探讨氨氯地平贝那普利片在老年高血压合并急性心肌梗死(AMI)患者中的临床疗效。方法回顾性分析2018年1月至2021年6月沈阳医学院附属第二医院收治的407例年龄>75岁的高血压合并AMI患者的临床资料,根据使用药物的不同分为氨氯地平... 目的探讨氨氯地平贝那普利片在老年高血压合并急性心肌梗死(AMI)患者中的临床疗效。方法回顾性分析2018年1月至2021年6月沈阳医学院附属第二医院收治的407例年龄>75岁的高血压合并AMI患者的临床资料,根据使用药物的不同分为氨氯地平贝那普利组(n=304)与贝那普利单药治疗组(n=103)。比较两组临床资料、实验室检查及彩色多普勒超声指标、不良心脑血管事件发生情况,并采用单因素及多因素Logistic回归分析院内死亡的危险因素。结果氨氯地平贝那普利组入院时血压、心率及硝酸酯类药物使用率均高于贝那普利组,但合并心房颤动占比低于贝那普利组,差异有统计学意义(P<0.05)。氨氯地平贝那普利组WBC、血肌酐、心肌肌钙蛋白I水平均低于贝那普利组,甘油三酯及估算的肾小球滤过率水平均高于贝那普利组,差异有统计学意义(P<0.05)。氨氯地平贝那普利组院内死亡率低于贝那普利组,差异有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,高B型脑钠肽(BNP)水平、心率较快及贝那普利单药治疗是院内死亡的独立危险因素(P<0.05)。结论氨氯地平贝那普利可降低老年高血压合并AMI患者院内死亡率,而高BNP水平及心率较快是院内死亡的独立危险因素,应用氨氯地平贝那普利可减少院内死亡事件的发生。 展开更多
关键词 贝那普利 氨氯地平 急性心肌梗死 高血压
下载PDF
Efficacy and safety of the treatment: combination of benazepril/ lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension 被引量:2
14
作者 CHEN Ting CHEN Guang-hui YANG Ting-shu ZHONG Zhen-yu AN Wei-shuai ZHANG Xiao-xia LI Jia-dan 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第12期2286-2290,共5页
Background Combination therapy is an effective method to reduce the blood pressure (BP) for patients with hypertension.This study was performed to evaluate the efficacy and safety of benazepril/lercanidipine compare... Background Combination therapy is an effective method to reduce the blood pressure (BP) for patients with hypertension.This study was performed to evaluate the efficacy and safety of benazepril/lercanidipine compared with benazepril alone in patients with mild-to-moderate hypertension.Methods One hundred and eighty-one patients with mild-to-moderate primary hypertension were assigned in this randomized,single-blind,parallel-group study and were randomly divided into group A (benazepril 10 mg/lercanidipine 10 mg) and group B (benazepril 10 mg) for 8 weeks.At 4 weeks,the dosage of Benazepril was titrated up to 20 mg if the diastolic blood pressure (DBP) remained ≥90 mmHg.BP control and side effects were evaluated at the end of 1,4 and 8 weeks.Results The baseline characteristics of the two groups were similar.The BP in both groups decreased from the baseline (P 〈0.05).At the end of 4 and 8 weeks,Benazepril/Lercanidipine produced greater BP reduction than Benazepril alone (P 〈0.05).The comparison of the rate of BP control for the benazepril/lercanidipine and benazepril groups at the end of 1,4,and 8 weeks were 41.2% vs.37.6% (P 〉0.05),67.1% vs.44.7% (P 〈0.05),and 71.8% vs.45.9% (P 〈0.05).There was no significant difference of side effects between the two groups.Conclusion The benazepril/lercanidipine combination is more effective in reducing BP than benazepril alone,while it does not increase the incidence of side effects. 展开更多
关键词 HYPERTENSION combination therapy benazepril LERCANIDIPINE
原文传递
E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients 被引量:1
15
作者 ZHANG Yan HONG Xiu-mei +3 位作者 XING Hou-xun Li Jian-ping HUO Yong XU Xi-ping 《Chinese Medical Journal》 SCIE CAS CSCD 2009年第20期2461-2465,共5页
Background Marked interindividual variation exists in blood pressure response to benazepril, which is considered to have genetic basis. Our objectives were to evaluate whether the E112D polymorphism in the prolylcarbo... Background Marked interindividual variation exists in blood pressure response to benazepril, which is considered to have genetic basis. Our objectives were to evaluate whether the E112D polymorphism in the prolylcarboxypeptidase (PRCP) gene has impact on blood pressure response to benazepril. Methods Hypertensive patients from Huoqiu County and Yuexi County of Anhui Province received daily treatment with an oral dosage of 10 mg benazepril for 15 days. Genotypes of the E112D polymorphism in the PRCP gene were determined by TaqMan SNP genotyping assay. Multivariate linear and Logistic regressions using generalized estimating equation model were performed in a total of 1092 patients to evaluate the association of PRCP genotypes and blood pressure response to benazepril. Results Patients carrying ED or DD genotype had a less systolic blood pressure reduction (adjusted 13= -3.7±1.1, P 〈0.001), a less diastolic blood pressure reduction (adjusted β= -3.1±0.8, P 〈0.001) and a lower percentage of reaching target blood pressure defined as SBP lower than 140 mmHg and DBP lower than 90 mmHg (adjusted OR=0.6, P=0.005) than those patients carrying EE genotype. In addition, the results from stratified analysis by county (Huoqiu or Yuexi) were similar to those observed in the pooled population. Conclusions Our data suggest that the E112D polymorphism in the PRCP gene may be a useful genetic marker to predict the antihypertensive effect of short-term benazepril treatment in hypertensive Datients of Anhui Province. China. 展开更多
关键词 benazepril PROLYLCARBOXYPEPTIDASE POLYMORPHISM HYPERTENSION
原文传递
应用动态血压监测仪及人体成分分析仪观察氨氯地平贝那普利片(Ⅱ)对原发性高血压患者的疗效
16
作者 唐聪敏 闫荣 +2 位作者 李雪辉 丁文静 邢艳秋 《中国实用医药》 2024年第5期100-103,共4页
目的 评价动态血压监测仪及人体成分分析仪在氨氯地平贝那普利片(Ⅱ)治疗原发性高血压患者疗效中的作用。方法 110例原发性高血压患者,入组前停用既往所有降压药,洗脱期间,饮食方式不变。2周之后接受氨氯地平贝那普利片(Ⅱ)治疗,监测并... 目的 评价动态血压监测仪及人体成分分析仪在氨氯地平贝那普利片(Ⅱ)治疗原发性高血压患者疗效中的作用。方法 110例原发性高血压患者,入组前停用既往所有降压药,洗脱期间,饮食方式不变。2周之后接受氨氯地平贝那普利片(Ⅱ)治疗,监测并比较患者治疗前后动态血压参数(白天、夜间、24 h的收缩压和舒张压)、平滑指数、人体成分[骨骼肌质量、脂肪含量、骨骼肌质量指数(SMI)]。结果 治疗后,白天、夜间、24 h的收缩压分别为(132.58±11.22)、(120.23±12.83)、(126.10±8.11)mm Hg(1 mm Hg=0.133 kPa),均低于治疗前的(148.36±10.42)、(133.11±12.91)、(142.26±10.15)mm Hg,舒张压分别为(75.65±11.96)、(68.31±9.10)、(71.40±8.70)mm Hg,均低于治疗前的(85.03±10.98)、(77.85±10.84)、(83.92±9.89)mm Hg,治疗后的平滑指数(2.00±0.23)高于治疗前的(1.21±0.26),差异具有统计学意义(P<0.01)。患者治疗后的骨骼肌质量(35.75±6.84)kg、SMI(8.38±0.51)kg/m2均高于治疗前的(25.15±6.58)kg、(7.95±0.44)kg/m2,脂肪含量(18.83±4.15)kg低于治疗前的(23.12±4.51)kg,差异具有统计学意义(P<0.01)。结论 氨氯地平贝那普利片(Ⅱ)能有效平稳地降低原发性高血压患者的动态血压,且增加骨骼肌质量、降低脂肪含量,优化人体成分,值得临床推广。 展开更多
关键词 氨氯地平贝那普利片(Ⅱ) 原发性高血压 动态血压 人体成分
下载PDF
金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病疗效观察 被引量:1
17
作者 焦书沛 杨会杰 《实用中医药杂志》 2024年第2期244-246,共3页
目的:观察金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病的临床疗效。方法:74例按照随机数字表法分为对照组与研究组各37例,两组均用达格列净和贝那普利治疗,研究组加用金匮肾气丸。结果:研究组总有效率与估算肾小球滤过率(eGFR)水平高于对照组(P<... 目的:观察金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病的临床疗效。方法:74例按照随机数字表法分为对照组与研究组各37例,两组均用达格列净和贝那普利治疗,研究组加用金匮肾气丸。结果:研究组总有效率与估算肾小球滤过率(eGFR)水平高于对照组(P<0.05),中医证候积分、血肌酐(SCR)、血尿素氮(BUN)、24h尿总量蛋白(TUP)和尿微量白蛋白/尿肌酐(UMA/UCR)以及空腹血糖(FBG)水平均低于对照组(P<0.05)。结论:金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病可提高疗效。 展开更多
关键词 Ⅱ-Ⅲ期糖尿病肾病 金匮肾气丸 达格列净 贝那普利
下载PDF
氨氯地平联合贝那普利治疗高血压的效果观察
18
作者 马珍妮 《中国现代药物应用》 2024年第7期81-83,共3页
目的研究氨氯地平联合贝那普利治疗高血压的疗效。方法135例高血压患者,根据用药方式不同分为观察组(68例)和对照组(67例)。对照组给予氨氯地平口服治疗,观察组给予氨氯地平联合贝那普利口服治疗。比较两组血压控制优良率,血压、心率水... 目的研究氨氯地平联合贝那普利治疗高血压的疗效。方法135例高血压患者,根据用药方式不同分为观察组(68例)和对照组(67例)。对照组给予氨氯地平口服治疗,观察组给予氨氯地平联合贝那普利口服治疗。比较两组血压控制优良率,血压、心率水平,用药不良反应发生率。结果观察组的血压控制优良率97.06%(66/68)高于对照组的83.58%(56/67),差异有统计学意义(P<0.05)。治疗前,两组收缩压、舒张压和心率对比差异无统计学意义(P>0.05);治疗后,两组收缩压、舒张压、心率均低于治疗前,且观察组收缩压(121.18±23.61)mm Hg(1 mm Hg=0.133 kPa)、舒张压(82.32±16.04)mm Hg、心率(69.53±13.55)次/min低于对照组的(130.27±25.19)mm Hg、(88.85±17.18)mm Hg、(76.46±14.79)次/min,差异有统计学意义(P<0.05)。两组用药不良反应发生率对比差异无统计学意义(P>0.05)。结论高血压患者采用氨氯地平联合贝那普利治疗能够控制患者的血压和心率水平,提升血压控制优良率,且保证用药安全,值得推荐。 展开更多
关键词 氨氯地平 贝那普利 高血压 心率 血压控制
下载PDF
乌拉地尔联合贝那普利对冠心病合并心力衰竭患者心功能及氨基末端脑钠肽的影响
19
作者 潘永跃 李迪 诸骁丽 《中国药物与临床》 CAS 2024年第9期590-594,共5页
目的探讨乌拉地尔联合贝那普利对冠心病合并心力衰竭患者氨基末端脑钠肽前体(NT-proBNP)及心功能的影响。方法以2021年9月至2023年9月浙江省青春医院收治的118例冠心病合并心力衰竭患者作为研究对象,以随机数表法将其分为对照组(给予贝... 目的探讨乌拉地尔联合贝那普利对冠心病合并心力衰竭患者氨基末端脑钠肽前体(NT-proBNP)及心功能的影响。方法以2021年9月至2023年9月浙江省青春医院收治的118例冠心病合并心力衰竭患者作为研究对象,以随机数表法将其分为对照组(给予贝那普利治疗),观察组(给予贝那普利+乌拉地尔治疗),每组59例。比较2组临床疗效、心功能、炎性细胞因子、NT-proBNP水平并观察不良反应发生情况。结果观察组临床总有效率(90%)较对照组(73%)高(χ^(2)=5.587,P<0.05)。观察组治疗2周后左心室射血分数(LVEF)、心排血量(CO)[(49.7±3.2)%、(5.2±0.4)L/min]高于对照组[(47.9±3.8)%、(4.9±0.5)L/min],左心室收缩末期内径(LVESD)(36.0±3.0)mm短于对照组(39.8±3.2)mm(t=2.824,P=0.006;t=3.009,P=0.002;t=6.651,P<0.01);观察组治疗2周后超敏C反应蛋白(hs-CRP)、NT-proBNP水平[(6.5±1.3)mg/L、(796±23)pg/L]低于对照组[(8.0±1.5)mg/L、(1490±219)pg/ml](t=5.639,P<0.01;t=24.231,P<0.01)。2组不良反应发生率(8%与5%)比较,差异无统计学意义(χ^(2)=0.536,P=0.464)。结论在冠心病合并心力衰竭患者予以乌拉地尔与贝那普利联合治疗,可有效降低患者NT-proBNP及炎症水平,改善其心功能,且安全性较高。 展开更多
关键词 心力衰竭 乌拉地尔 贝那普利 心功能 氨基末端脑钠肽前体
下载PDF
分析氯沙坦联合贝那普利对肾实质性高血压患者血压水平及肾功能的影响
20
作者 蔡丽 《中国实用医药》 2024年第9期80-83,共4页
目的分析氯沙坦与贝那普利联合治疗对肾实质性高血压患者血压水平、肾功能的影响。方法选取120例肾实质性高血压患者,按随机数字表法分为对照组及研究组,各60例。对照组给予贝那普利进行治疗,研究组给予氯沙坦与贝那普利联合治疗。比较... 目的分析氯沙坦与贝那普利联合治疗对肾实质性高血压患者血压水平、肾功能的影响。方法选取120例肾实质性高血压患者,按随机数字表法分为对照组及研究组,各60例。对照组给予贝那普利进行治疗,研究组给予氯沙坦与贝那普利联合治疗。比较两组患者治疗前后的血压(舒张压、收缩压)及肾功能指标(24 h尿蛋白定量、血肌酐)水平,不良反应发生情况。结果治疗后,两组患者的舒张压、收缩压均低于本组治疗前,且研究组的舒张压(80.25±3.89)mm Hg(1 mm Hg=0.133 kPa)、收缩压(123.06±12.56)mm Hg比对照组的(87.87±4.93)、(131.46±10.92)mm Hg低,差异有统计学意义(P<0.05)。治疗后,两组24 h尿蛋白定量、血肌酐均低于本组治疗前,且研究组24 h尿蛋白定量(1.23±0.08)g/24 h、血肌酐(127.13±13.62)μmol/L低于对照组的(1.52±0.14)g/24 h、(143.14±16.17)μmol/L,差异有统计学意义(P<0.05)。治疗后,研究组不良反应发生率6.67%比对照组的21.67%低,差异有统计学意义(P<0.05)。结论氯沙坦与贝那普利联合治疗肾实质性高血压患者的效果较好,能有效改善患者的血压指标及肾功能情况,且减少不良反应,有一定临床应用与研究价值。 展开更多
关键词 氯沙坦 贝那普利 肾实质性高血压 血压水平 肾功能
下载PDF
上一页 1 2 85 下一页 到第
使用帮助 返回顶部